Most biotech and medtech teams that lose grant money do not lose it by being ineligible. They lose it by putting a correct cost in the wrong line. The three grant budget rules below come up in almost every budget review: one from Horizon Europe, one from US federal...
Scientific breakthroughs get attention for good reason. They are the moments when something that did not exist before suddenly becomes possible. But anyone who has spent time trying to commercialize biotechnology learns another lesson pretty quickly: proving that...
The ANI Egetis offer pays SEK 11.25 a share in cash, about $560 million in total. See the premiums, conditions and expected timetable.
Artificial intelligence and the buzz around it feel like they're moving at warp speed. As this acceleration continues, especially in the life sciences, we need to pause and understand the vast differences between two uses of artificial intelligence that couldn’t be...
CAR T-cell therapy is revolutionizing cancer treatment and being applied to a variety of other indications, but the approach relies on engineering a patient’s immune cells to recognize and attack cancer. Producing those cells can involve a complex, resource- and...
The AbbVie Nxera deal gives AbbVie global IBD rights to oral EP4 agonist NXE0033744 for $100 million upfront. Antitrust clearance is pending.
The AbbVie Nxera deal gives AbbVie exclusive worldwide rights to develop and commercialise NXE0033744 in inflammatory bowel disease (IBD). The price is $100 million upfront, plus up to $1.37 billion in milestones and tiered royalties. Nxera Pharma announced the...
No COMP360 approval date exists yet, but the timetable is short. Compass Pathways said its rolling new drug application (NDA) should finish “in the next two weeks”. It made the statement on 3 November 2026, in its third-quarter 2026 results release. The company...
The BioMarin Fabry deal gives the US company exclusive worldwide rights, outside Korea, to an early-stage injectable enzyme therapy. BioMarin announced the licence on 29 October 2026 with GC Biopharma and Hanmi Pharm. The candidate is HM15421/GC1134A, also known as...
Extracellular vesicles are attracting growing attention in neurology because they can carry proteins, lipids and nucleic acids between cells and may reflect aspects of the biological state of their cells of origin. Their potential applications include liquid-biopsy...
BBP-418 approval is due to be decided by the US Food and Drug Administration (FDA) by 27 November 2026. That is the target action date for BridgeBio’s oral treatment for limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9). BioSpace reported on 2 November 2026 that...
Image duplication, one of the most common image integrity problems in published research, can result from an inadvertent mix-up during figure preparation, reuse that has not been clearly explained, or deliberate fabrication. A 2025 analysis of the Retraction Watch...
The Ferring Gameto acquisition would give Ferring Pharmaceuticals control of Fertilo, Gameto’s lead investigational fertility programme. Fertilo is derived from induced pluripotent stem cells and is designed to mature eggs outside the body. Ferring and Gameto...
Under the ZW209 licensing deal with Zymeworks, Roche will receive exclusive global rights to develop and commercialise ZW209. In return, Zymeworks is due $55 million upfront and $40 million when a Phase 1b trial begins. It is also eligible for up to $718 million in...
UK biotech venture capital reached £2.84 billion in the first nine months of 2026. That is more than in any full year from 2022 to 2025. The figures come from the BioIndustry Association (BIA) Q3 2026 financing report, published on 26 October 2026 [1]. The BIA puts...
In preclinical oncology, a tumor study can show little benefit even when a candidate has strong activity in cultured cells. Before abandoning the compound, researchers need to establish what the result means. Did enough drug reach the tumor? Was the proposed target...
For much of the past decade, exosomes have occupied a familiar place in biotechnology: scientifically intriguing, biologically versatile and full of potential, but still some distance from becoming routinely manufactured products. That is beginning to change as...
Ilofotase alfa now belongs to Ambrose Healthcare, a UK-headquartered rare disease company. On 20 October 2026, Ambrose said it had acquired 100 per cent of the shares of AM-Pharma. The Dutch company, based in Utrecht, developed the drug. The deal is complete rather...